Detalhe da pesquisa
1.
A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer.
Proc Natl Acad Sci U S A
; 121(4): e2318093121, 2024 Jan 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38232291